Background: Recent investigations have shown that proteins, including Bet v 1a, are nitrated by exposure to polluted urban air. We have investigated immunogenic and allergenic properties of in vitro nitrated allergens in in vivo models. Methods: Untreated and nitrated samples of ovalbumin or Bet v 1a were compared for their ability to stimulate proliferation and cytokine secretion in splenocytes from DO11.10 or from sensitized BALB/c mice, and for their ability to induce specific immunoglobulin (Ig)G1, IgG2a and IgE in sensitized mice. Additionally, sera from birch pollen-allergic individuals were analysed for IgE and IgG specific for nitrated Bet v 1a. Results: Upon splenocyte stimulation with nitrated as compared with unmodified allergens, proliferation as well as interleukin 5 and interferon-γ production were enhanced. Sera of mice sensitized with nitrated allergens showed elevated levels of specific IgE, IgG1 and IgG2a, compared with sera from mice sensitized with unmodified allergens. Moreover, cross-reactivity of antibodies against unrelated, nitrated allergens was observed in mice. We also found higher amounts of functional, specific IgE against nitrated than against untreated Bet v 1a in sera from birch pollen-allergic patients. Conclusions: Our findings suggest that nitration enhances allergic responses, which may contribute to an increased prevalence of allergic diseases in polluted urban environments.

Keywords:
Air pollution, Bet v 1, Epitopes, Immunoglobulin E, Nitration, Nitrotyrosine, Ovalbumin
1.
Bernstein JA, Alexis N, Barnes C, Bernstein IL, Nel A, Peden D, Diaz-Sanchez D, Tarlo SM, Williams PB: Health effects of air pollution. J Allergy Clin Immunol 2004;114:1116–1123.
2.
Bömmel H, Li-Weber M, Serfling E, Duschl A: The environmental pollutant pyrene induces the production of IL-4. J Allergy Clin Immunol 2000;105:796–802.
3.
D’Amato G: Urban air pollution and plant-derived respiratory allergy. Clin Exp Allergy 2000;30:628–636.
4.
Saxon A, Diaz-Sanchez D: Air pollution and allergy: you are what you breathe. Nat Immunol 2005;6:223–226.
5.
Brunekreef B: NO2: the gas that won’t go away. Clin Exp Allergy 2001;31:1170–1172.
6.
Franze T, Weller MG, Niessner R, Pöschl U: Protein nitration by polluted air. Environ Sci Technol 2005;39:1673–1678.
7.
Doyle HA, Mamula MJ: Posttranslational modifications of self-antigens. Ann NY Acad Sci 2005;1050:1–9.
8.
Ferreira F, Ebner C, Kramer B, Casari G, Briza P, Kungl AJ, Grimm R, Jahn-Schmid B, Breiteneder H, Kraft D, Breitenbach M, Rheinberger HJ, Scheiner O: Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J 1998;12:231–242.
9.
Spangfort MD, Mirza O, Ipsen H, Van Neerven RJ, Gajhede M, Larsen JN: Dominating IgE-binding epitope of Bet v 1, the major allergen of birch pollen, characterized by X-ray crystallography and site-directed mutagenesis. J Immunol 2003;171:3084–3090.
10.
Greenacre SA, Ischiropoulos H: Tyrosine nitration: localisation, quantification, consequences for protein function and signal transduction. Free Radic Res 2001;34:541–581.
11.
Birnboim HC, Lemay AM, Lam DK, Goldstein R, Webb JR: Cutting edge: MHC class II-restricted peptides containing the inflammation-associated marker 3-nitrotyrosine evade central tolerance and elicit a robust cell-mediated immune response. J Immunol 2003;171:528–532.
12.
Ohmori H, Oka M, Nishikawa Y, Shigemitsu H, Takeuchi M, Magari M, Kanayama N: Immunogenicity of autologous IgG bearing the inflammation-associated marker 3-nitrotyrosine. Immunol Lett 2005;96:47–54.
13.
Peplow M: Traffic pollution revs up allergens. [email protected] 2005;DOI:10.1038/news050131-16.
14.
Franze T, Weller MG, Niessner R, Pöschl U: Enzyme immunoassays for the investigation of protein nitration by air pollutants. Analyst 2003;128:824–831.
15.
Franze T, Weller MG, Niessner R, Pöschl U: Comparison of nitrotyrosine antibodies and development of immunoassays for the detection of nitrated proteins. Analyst 2004;129:589–596.
16.
Walcher W, Franze T, Weller MG, Pöschl U, Huber CG: Liquid- and gas-phase nitration of bovine serum albumin studied by LC-MS and LC-MS/MS using monolithic columns. J Proteome Res 2003;2:534–542.
17.
Murphy KM, Heimberger AB, Loh DY: Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science 1990;250:1720–1723.
18.
Hochreiter R, Stepanoska T, Ferreira F, Valenta R, Vrtala S, Thalhamer J, Hartl A: Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen. Eur J Immunol 2003;33:1667–1676.
19.
Hoffmann A, Kaul S, Fotisch K, Danz N, Luttkopf D, Hatahet L, Kastner B, Vogel L, Holtz G, Vieths S: Mediator release assays based on human and murine IgE: potential and limitations in allergen standardization. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 2003:76–85; discussion 85–86.
20.
Hartl A, Weiss R, Hochreiter R, Scheiblhofer S, Thalhamer J: DNA vaccines for allergy treatment. Methods 2004;32:328–339.
21.
Backlund J, Carlsen S, Hoger T, Holm B, Fugger L, Kihlberg J, Burkhardt H, Holmdahl R: Predominant selection of T cells specific for the glycosylated collagen type II epitope (263–270) in humanized transgenic mice and in rheumatoid arthritis. Proc Natl Acad Sci USA 2002;99:9960–9965.
22.
Pierce RA, Field ED, den Haan JM, Caldwell JA, White FM, Marto JA, Wang W, Frost LM, Blokland E, Reinhardus C, Shabanowitz J, Hunt DF, Goulmy E, Engelhard VH: Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. J Immunol 1999;163:6360–6364.
23.
Zarling AL, Ficarro SB, White FM, Shabanowitz J, Hunt DF, Engelhard VH: Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. J Exp Med 2000;192:1755–1762.
24.
Breiteneder H, Friedl-Hajek R, Ebner C, Schenk S, Fischer G, Kraft D, Scheiner O: Sequence comparisons of the CDR3 hyper-variable loops of human T cell receptors specific for three major T cell epitopes of the birch pollen allergen Bet v 1. Mol Immunol 1996;33:1039–1048.
25.
Ebner C, Szepfalusi Z, Ferreira F, Jilek A, Valenta R, Parronchi P, Maggi E, Romagnani S, Scheiner O, Kraft D: Identification of multiple T cell epitopes on Bet v I, the major birch pollen allergen, using specific T cell clones and overlapping peptides. J Immunol 1993;150:1047–1054.
26.
Friedl-Hajek R, Spangfort MD, Schou C, Breiteneder H, Yssel H, Joost van Neerven RJ: Identification of a highly promiscuous and an HLA allele-specific T-cell epitope in the birch major allergen Bet v 1: HLA restriction, epitope mapping and TCR sequence comparisons. Clin Exp Allergy 1999;29:478–487.
27.
Jahn-Schmid B, Radakovics A, Luttkopf D, Scheurer S, Vieths S, Ebner C, Bohle B: Bet v 1142–1156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1-related food allergens. J Allergy Clin Immunol 2005;116:213–219.
28.
Ferreira F, Hirtenlehner K, Jilek A, Godnik-Cvar J, Breiteneder H, Grimm R, Hoffmann-Sommergruber K, Scheiner O, Kraft D, Breitenbach M, Rheinberger HJ, Ebner C: Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. J Exp Med 1996;183:599–609.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.